The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better.
Loria F, Mone P, Rispoli A, Di Fonzo R, Masarone D, Mancusi C, Correale M, Vitullo A, Granatiero M, Mazzeo P, Mercurio V, Fiore F, Di Sarro E, Falco L, Izzo C, Campanile A, Virtuoso N, Stabile E, Bonanno S, Dattilo G, Tocchetti CG, Santulli G, Vecchione C, Ciccarelli M, Visco V.
Loria F, et al. Among authors: falco l.
Cardiovasc Diabetol. 2024 Nov 22;23(1):423. doi: 10.1186/s12933-024-02515-5.
Cardiovasc Diabetol. 2024.
PMID: 39578847
Free PMC article.